Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Contract/Agreement, Product/Service, Funding

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines


NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines.

Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial. NEC and VAXIMM will co-develop personalized cancer vaccines using NEC's cutting-edge artificial intelligence (AI) technology, which is utilized in its Neoantigen Prediction System, and VAXIMM's proprietary T-cell immunotherapy technology. The vaccines are planned to be evaluated in a Phase I clinical trial in various solid tumors. VAXIMM will be responsible for conducting the clinical trial, which is expected to be initiated in 2020.

NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan.

Osamu Fujikawa, Senior Vice President, NEC Corporation, said: "Cancer is consistently one of the most serious healthcare challenges, with millions of new cases diagnosed worldwide annually. NEC's core technology is well positioned for the development of personalized medicine, and we are strongly committed to delivering effective treatments for cancer patients. We are delighted to be working with VAXIMM in order to develop an optimal immunotherapy for each individual patient."

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of VAXIMM, said: "We are excited to enter this alliance with NEC and to have their strong support of VAXIMM. NEC's novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient, facilitating the optimal potential treatment for each individual. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. Individualized therapy is at the cutting edge of cancer treatment today, and, with this collaboration, we are able to further contribute to this approach."

Notes:

About NEC's AI Drug Development Business
For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/

About NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary AI which is combined with NEC OncoImmunity AS's bioinformatics pipelines ? making it the leading neoantigen prediction system in the field. NEC comprehensively evaluates candidate neoantigens, which allows it to effectively prioritize numerous candidate neoantigens identified in a single patient.

Press release:
NEC acquires Norwegian bioinformatics company, OncoImmunity AS
https://www.nec.com/en/press/201907/global_20190729_01.html

About NEC Corporation
For more information, visit NEC at http://www.nec.com.

About VAXIMM
For more information, please see www.vaximm.com.


These press releases may also interest you

at 12:50
Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcR?-deficient natural killer (G-NK) cell therapy to treat multiple cancers, today...

at 12:45
Medchart, a North-American digital medical records retrieval service, and the Chicago Bar Association (CBA) have announced a new Member Benefit partnership. As part of the agreement, all members of the 20,000-member strong CBA will have the...

at 12:30
ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New York-based pharmaceutical company Kures, which targets the important intersection between pain and opioid...

at 12:30
With COVID-19 cases on the rise in many parts of the country and health officials urging vigilant use of masks as protection, the American Speech-Language-Hearing Association (ASHA) is providing advice for people with and without hearing loss to help...

at 12:25
Bioservo Technologies AB has signed a distribution agreement with CAS Assembly Tooling and Services for selling Ironhand® in the United Kingdom. CAS Assembly Tooling and Services are a market leader in supplying, installing and servicing production...

at 12:24
The Ontario Nurses' Association (ONA) has serious concerns that while Ontarians are preoccupied with the COVID-19 pandemic, the Ford government has passed Bill 175, the province's home and community healthcare legislation. The bill, says ONA, fails...



News published on 11 november 2019 at 21:55 and distributed by: